Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05824403

PAncreatic Disease Cohort of TOuLouse

This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rangueil hospital

Toulouse, France

Location status: Recruiting

Location contact

Adrian CULETTO, MD

SUB_INVESTIGATOR

Barbara BOURNET, MD

CONTACT

[email protected]

0561323235

Charlotte MAULAT, MD

SUB_INVESTIGATOR

Fabrice MUSCARI, MD

SUB_INVESTIGATOR

Karl BARANGE, MD

SUB_INVESTIGATOR

Louis BUSCAIL, MD

SUB_INVESTIGATOR

Nicolas CARRERE, MD

SUB_INVESTIGATOR

About this study

This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with inflammatory or cystic exocrine pancreatic pathology
  • Patient able to read and understand the information leaflet
  • Patients who have agreed to participate in the study and have signed the free and informed consent
  • Patients affiliated to a social security system (including AME)

Exclusion criteria

  • Patient with pancreatic cancer pathology
  • Patients with active cancer, whatever the origin
  • Pregnant or breastfeeding patients
  • Patients under legal protection, guardianship or trusteeship

Treatment and study plan

Primary outcomes

  1. Diagnostic tools

    Time frame: 3 years after the first inclusion

    To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies

Secondary outcomes

  1. New targets

    Time frame: 3 years after the first inclusion

    To identify new screening targets

  2. Improvement of management

    Time frame: 3 years after the first inclusion

    To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management

  3. Microbiota

    Time frame: 3 years after the first inclusion

    Study of the microbiota of pancreatic diseases

  4. Clinical data access

    Time frame: 3 years after the first inclusion

    To make available to the scientific community quality material with associated clinical data also of quality

Study contacts

Contact information is provided by the study sponsor or research team.

Barbara BOURNET, MD

CONTACT

[email protected]

0561323235 ext. +33

Cindy CANIVET

CONTACT

[email protected]

05 61 32 20 48

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Acronym: PACTOL

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Apr 21, 2023
Registry last updated
Dec 4, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.